IS7629A - Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu - Google Patents

Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu

Info

Publication number: IS7629A
Authority: IS; Iceland
Prior art keywords: exchangeable; diabetic; obesity agent; method useful; heterocyclic derivatives
Prior art date: 2002-07-09

Application number

IS7629A

Other languages

English (en)

Inventor

T. W. Cheng Peter

Chen Sean

Z. Ding Charles

F. Herpin Timothy

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-09

Filing date

2005-01-05

Publication date

2005-01-05

2005-01-05 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2005-01-05 Publication of IS7629A publication Critical patent/IS7629A/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IS7629A 2002-07-09 2005-01-05 Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu IS7629A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39455302P	2002-07-09	2002-07-09
PCT/US2003/021331 WO2004004655A2 (en)	2002-07-09	2003-07-08	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Publications (1)

Publication Number	Publication Date
IS7629A true IS7629A (is)	2005-01-05

Family

ID=30115733

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7629A IS7629A (is)	2002-07-09	2005-01-05	Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu

Country Status (23)

Country	Link
US (2)	US6875782B2 (is)
EP (1)	EP1531810B1 (is)
JP (1)	JP4541883B2 (is)
KR (1)	KR101120337B1 (is)
CN (1)	CN1665500A (is)
AT (1)	ATE543497T1 (is)
AU (1)	AU2003248861B2 (is)
BR (1)	BR0312503A (is)
CA (1)	CA2490972C (is)
ES (1)	ES2380319T3 (is)
GE (1)	GEP20084475B (is)
HR (1)	HRP20050001A2 (is)
IL (1)	IL165809A (is)
IS (1)	IS7629A (is)
MX (1)	MXPA05000279A (is)
NO (1)	NO329328B1 (is)
NZ (1)	NZ537251A (is)
PL (1)	PL375230A1 (is)
RS (1)	RS20050002A (is)
RU (1)	RU2325381C2 (is)
UA (1)	UA79296C2 (is)
WO (1)	WO2004004655A2 (is)
ZA (1)	ZA200500029B (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060058395A1 (en) *	2002-08-01	2006-03-16	Neurosearch A/S	Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
US20060183897A1 (en) *	2003-03-18	2006-08-17	Chakravarty Prasun K	Biaryl substituted triazoles as sodium channel blockers
MY142651A (en) *	2003-03-18	2010-12-15	Merck Sharp & Dohme	Biaryl substituted triazoles as sodium channel blockers
KR20050122220A (ko)	2003-03-25	2005-12-28	다케다 샌디에고, 인코포레이티드	디펩티딜 펩티다제 억제제
WO2004103993A1 (en)	2003-05-14	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
BRPI0413452A (pt)	2003-08-13	2006-10-17	Takeda Pharmaceutical	composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
FR2861303A1 (fr) *	2003-10-24	2005-04-29	Sanofi Synthelabo	Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2861302A1 (fr) *	2003-10-24	2005-04-29	Sanofi Synthelabo	Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861301B1 (fr) *	2003-10-24	2008-07-11	Sanofi Synthelabo	Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861300B1 (fr) *	2003-10-24	2008-07-11	Sanofi Synthelabo	Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
JP2007512359A (ja) *	2003-11-19	2007-05-17	メタバシス・セラピューティクス・インコーポレイテッド	新規なリン含有甲状腺ホルモン様物質
WO2006128058A2 (en)	2005-05-26	2006-11-30	Metabasis Therapeutics, Inc.	Thyromimetics for the treatment of fatty liver diseases
NZ549721A (en)	2004-03-05	2010-08-27	Univ Pennsylvania	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US20060014785A1 (en) *	2004-05-25	2006-01-19	Metabolex, Inc.	Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
WO2005115383A2 (en) *	2004-05-25	2005-12-08	Metabolex, Inc.	Substituted triazoles as modulators of ppar and methods of their preparation
US20060058224A1 (en) *	2004-09-15	2006-03-16	Yancopoulos George D	Methods of treating obesity with combination therapeutics
CA2581596A1 (en) *	2004-09-29	2006-04-13	Schering Corporation	Combinations of substituted azetidonones and cb1 antagonists
WO2006105127A2 (en)	2005-03-31	2006-10-05	Takeda San Diego, Inc.	Hydroxysteroid dehydrogenase inhibitors
WO2006117743A1 (en) *	2005-05-03	2006-11-09	Ranbaxy Laboratories Limited	Substituted aromatic compounds as antidiabetic agents
RU2007148927A (ru) *	2005-05-26	2009-07-10	Метабэйзис Терапьютикс, Инк. (Us)	Новые тиреомиметики, содержащие фосфиновую кислоту
FR2889191A1 (fr) *	2005-07-28	2007-02-02	Cerep Sa	Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1
GEP20135838B (en)	2005-09-14	2013-06-10	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors usage at diabetes treatment
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP2009511634A (ja) *	2005-10-18	2009-03-19	エージェリオンファーマシューティカルズ	哺乳動物において高脂血症に関連する障害を治療する方法
US8003676B2 (en) *	2006-05-30	2011-08-23	Astrazeneca Ab	1,3,4-oxadiazole derivatives as DGAT1 inhibitors
ATE492541T1 (de) *	2006-05-30	2011-01-15	Astrazeneca Ab	Substituierte 5-phenylamino-1,3,4-oxadiazol-2- ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a- diacylglycerolacyltransferase
US20080009534A1 (en) *	2006-07-07	2008-01-10	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8217025B2 (en) *	2006-11-17	2012-07-10	Harbor Therapeutics, Inc.	Drug screening and treatment methods
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JP2010513534A (ja) *	2006-12-21	2010-04-30	エージェリオンファーマシューティカルズ，インコーポレイテッド	Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
TW200906823A (en)	2007-07-16	2009-02-16	Lilly Co Eli	Compounds and methods for modulating FXR
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
CN103694195B (zh) *	2013-09-18	2016-04-06	华东师范大学	芳香杂环类小分子有机化合物及衍生物、制备方法及医药用途
EP3190103A1 (en) *	2016-01-08	2017-07-12	Rijksuniversiteit Groningen	Inhibitors of the pd-1/pd-l1 protein/protein interaction
KR20190104524A (ko)	2016-11-21	2019-09-10	바이킹 테라퓨틱스 인코포레이티드	당원축적질환의 치료 방법
BR112019025659A2 (pt)	2017-06-05	2020-08-25	Viking Therapeutics, Inc.	composições para o tratamento de fibrose
KR101943382B1 (ko)	2017-09-19	2019-01-29	오토텔릭바이오 주식회사	Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
ES3053674T3 (en)	2018-03-22	2026-01-23	Viking Therapeutics Inc	Crystalline forms and methods of producing crystalline forms of a compound
GB201810486D0 (en) *	2018-06-26	2018-08-08	Imperial Innovations Ltd	Natural killer cells
KR102131359B1 (ko) *	2018-09-07	2020-07-07	오토텔릭바이오 주식회사	안정성이 향상된 의약 조성물
EP3890747A4 (en)	2018-12-05	2022-08-03	Viking Therapeutics, Inc.	COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION
US20230285376A1 (en)	2020-07-29	2023-09-14	Amryt Pharmaceuticals Inc.	Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5686442A (en)	1993-12-28	1997-11-11	Meiji Seika Kabushiki Kaisha	Tricyclic benzazepine and benzothiazepine derivatives
ES2186720T3 (es) *	1994-05-27	2003-05-16	Merck & Co Inc	Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
EP0834512A4 (en)	1995-06-15	2001-08-22	Meiji Seika Kaisha	TRICLYCLIC BENZAZEPINE COMPOUNDS.
GB9604242D0 (en)	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
JP3215048B2 (ja) *	1996-04-03	2001-10-02	日本たばこ産業株式会社	プロピオン酸誘導体及びその用途
JPH1067759A (ja)	1996-06-20	1998-03-10	Sankyo Co Ltd	除草性アゾール誘導体
JPH11263775A (ja)	1997-09-08	1999-09-28	Sankyo Co Ltd	ヒドロキシアニリン誘導体
AU744636B2 (en)	1997-09-29	2002-02-28	Meiji Seika Pharma Co., Ltd.	Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic
DE69941777D1 (de)	1998-03-10	2010-01-21	Ono Pharmaceutical Co	Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
FR2778314B1 (fr)	1998-05-07	2002-06-14	Rhone Poulenc Agrochimie	Composition fongicide synergique comprenant un compose analogue de la strobilurine
GB9914977D0 (en) *	1999-06-25	1999-08-25	Glaxo Group Ltd	Chemical compounds
EP1210345B1 (en) *	1999-09-08	2004-03-03	Glaxo Group Limited	Oxazole ppar antagonists
US6414002B1 (en) *	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI302149B (en) *	1999-09-22	2008-10-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
JP3723071B2 (ja)	1999-11-10	2005-12-07	武田薬品工業株式会社	含窒素５員複素環化合物
GB0029974D0 (en) *	2000-12-08	2001-01-24	Glaxo Group Ltd	Chemical compounds

2003
- 2003-07-08 NZ NZ537251A patent/NZ537251A/en not_active IP Right Cessation
- 2003-07-08 HR HR20050001A patent/HRP20050001A2/hr not_active Application Discontinuation
- 2003-07-08 MX MXPA05000279A patent/MXPA05000279A/es active IP Right Grant
- 2003-07-08 BR BRPI0312503-3A patent/BR0312503A/pt not_active IP Right Cessation
- 2003-07-08 JP JP2004520018A patent/JP4541883B2/ja not_active Expired - Fee Related
- 2003-07-08 WO PCT/US2003/021331 patent/WO2004004655A2/en not_active Ceased
- 2003-07-08 RU RU2005103395/04A patent/RU2325381C2/ru not_active IP Right Cessation
- 2003-07-08 PL PL03375230A patent/PL375230A1/xx not_active Application Discontinuation
- 2003-07-08 AT AT03763345T patent/ATE543497T1/de active
- 2003-07-08 KR KR1020057000362A patent/KR101120337B1/ko not_active Expired - Fee Related
- 2003-07-08 RS YUP-2005/0002A patent/RS20050002A/sr unknown
- 2003-07-08 GE GEAP8617A patent/GEP20084475B/en unknown
- 2003-07-08 EP EP03763345A patent/EP1531810B1/en not_active Expired - Lifetime
- 2003-07-08 CN CN038160382A patent/CN1665500A/zh active Pending
- 2003-07-08 US US10/616,283 patent/US6875782B2/en not_active Expired - Lifetime
- 2003-07-08 ES ES03763345T patent/ES2380319T3/es not_active Expired - Lifetime
- 2003-07-08 CA CA2490972A patent/CA2490972C/en not_active Expired - Fee Related
- 2003-07-08 AU AU2003248861A patent/AU2003248861B2/en not_active Ceased
- 2003-08-07 UA UAA200501187A patent/UA79296C2/uk unknown
2004
- 2004-12-16 IL IL165809A patent/IL165809A/en not_active IP Right Cessation
- 2004-12-17 NO NO20045529A patent/NO329328B1/no not_active IP Right Cessation
- 2004-12-17 US US11/016,183 patent/US7507757B2/en not_active Expired - Lifetime
2005
- 2005-01-03 ZA ZA200500029A patent/ZA200500029B/xx unknown
- 2005-01-05 IS IS7629A patent/IS7629A/is unknown

Also Published As

Publication number	Publication date
RU2325381C2 (ru)	2008-05-27
US6875782B2 (en)	2005-04-05
US20040063762A1 (en)	2004-04-01
UA79296C2 (en)	2007-06-11
RU2005103395A (ru)	2005-08-10
HRP20050001A2 (en)	2005-08-31
JP2006501187A (ja)	2006-01-12
NZ537251A (en)	2007-02-23
PL375230A1 (en)	2005-11-28
WO2004004655A2 (en)	2004-01-15
WO2004004655A3 (en)	2004-10-14
KR20050025951A (ko)	2005-03-14
CA2490972A1 (en)	2004-01-15
US7507757B2 (en)	2009-03-24
NO329328B1 (no)	2010-09-27
ATE543497T1 (de)	2012-02-15
NO20045529L (no)	2005-02-03
CN1665500A (zh)	2005-09-07
JP4541883B2 (ja)	2010-09-08
BR0312503A (pt)	2007-06-26
EP1531810A4 (en)	2008-05-28
AU2003248861B2 (en)	2009-01-22
IL165809A0 (en)	2006-01-15
CA2490972C (en)	2012-05-29
RS20050002A (sr)	2007-09-21
GEP20084475B (en)	2008-09-10
EP1531810A2 (en)	2005-05-25
IL165809A (en)	2010-05-17
ES2380319T3 (es)	2012-05-10
MXPA05000279A (es)	2005-03-31
US20050119312A1 (en)	2005-06-02
ZA200500029B (en)	2006-06-28
KR101120337B1 (ko)	2012-02-29
AU2003248861A1 (en)	2004-01-23
EP1531810B1 (en)	2012-02-01

Publication	Publication Date	Title
IS7629A (is)	2005-01-05	Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu
IS7220A (is)	2004-04-15	Latar af þætti XA og öðrum rað-próteösum sem tengjast storknunar keðjuverkun
NO20000847D0 (no)	2000-02-21	Elastiske brønnsementsammensetninger og fremgangsmåter
HK10777456A1 (en)	2007-11-30	Sustained-release table composition of pramipexole
BR0317715A (pt)	2005-11-22	Composições e processos de uso de collajolie
DE60232456D1 (de)	2009-07-09	Härtbare zusammensetzung
ITVR20020006A1 (it)	2003-08-06	Ortesi per ginocchio ostoartritico
IS7519A (is)	2004-10-29	11-beta-hýdroxýstera vetnissviftir 1 hindrar nytsamlegir í meðferð við sykursýki, offitu og blóðfituröskun
NO20050077L (no)	2005-02-03	Substituerte heterocykliske derivater som er anvendelige som antidiabetes- og antiovervektsmidler
DE60214367D1 (de)	2006-10-12	Härtbare zusammensetzung
IS7060A (is)	2003-11-28	2,5-díarýlpýrasín, 2,5-díarýlpýridín og 2,5-díarýlpýrimidín sem CRF1 viðtakabeinar
ITPD20040244A1 (it)	2005-01-06	Tavola di mobilizzazione passiva dell'articolazione della caviglia.
ITBO20020068A0 (it)	2002-02-08	Unita' per l'alimentazione di componenti ad una stazione di montaggiodi almeno un componente su un pannello di legno o simili
DE60322926D1 (de)	2008-09-25	Photopolymerisierbare zusammensetzung und verwendung davon
AU2003290735A8 (en)	2004-06-30	Inhibitors of monoamine uptake
DE60331541D1 (de)	2010-04-15	Gaserzeugende Zusammensetzung
DK1487778T3 (da)	2012-08-06	Substituerede 4 aminocyclohexanoler
DE60216645D1 (de)	2007-01-18	Antiulcus pflanzenzusammensetzung(en)
DK1483317T3 (da)	2012-03-12	Svidningsinhibitorsammensætning med lav gulning
NO20033921D0 (no)	2003-09-04	Inhibitor av monoaminopptak
DE60206024D1 (de)	2005-10-13	Härtbare zusammensetzung
EA200800681A1 (ru)	2008-10-30	Применение киралаксила для защиты от фитопатогенов и соответствующие способы и композиции
DE50211891D1 (de)	2008-04-24	Härtbare cyanat-zusammensetzungen
DE60305870D1 (de)	2006-07-20	Kathodische elektro-überzugsmittel
DE50309042D1 (de)	2008-03-06	Piezoelektrisches bauelement